Capital Berg

Keeps People Up-To-Date

Tuesday, May 18, 2021
Log in

Sunscreen Saves You From Cancer

By

Sunscreen Saves You From Cancer

Sunscreen Saves You From Cancer

 

It is a known fact that sunscreen saves you from cancer and skin cancer is one of the most dangerous cancer types out there and the most commonly met. The number of affected people are rapidly growing, and in the time span of a year almost 3.5 million new cases get diagnosed.

The American Cancer Society informs us that exposure to sun without wearing any sunscreen is still the biggest cause for the contraction of this disease, and even though a lot of campaign were made with regard to fighting off skin cancer, people are still not taking this issue as seriously as they should.

Apart from the appearance of a melanoma, people encounter other risks as well, such as the early aging of skin, the appearance of dark blemishes, low levels of vitamins, such as vitamin D and some other subtle chemical imbalances whose effect will become obvious later in life.

People don’t always know what is right for them, and most of the time they choose a SPF factor that does not suit them, a much too lower one, especially people with fair skin. Scientists believe that not even a high SPF number is sufficient to go to the beach with no worries. What people need to find on the label is that the product will also protect them against UV A and UV B rays.

However, dermatologists have agreed that a product ranging in between 30-50 SPF is usually the best one and doctor Walt Sims from Skin Solutions Columbia underlined the fact the the product must necessarily contain zinc and titanium in order to be efficient. As a consequence, sun oil and similar products are quite inefficient at all. Moreover, the doctor suggests wearing sunscreen not only when going to the beach, but also when one is about to spend a lot of hours out in the sun.

Although people have been instructed so many times regarding the dangers of sun exposure, more and more people reach the hospitals each summer with serious cases of sunburn.

Image source: thestandardaily.com

Pfizer Proven Miracle To Fight Against ROS1 Lung Cancer Through Xalkori

By

Pfizer-xalkori-helpful-for-lung-cancer

In annual congress of European Society for Medical Oncology (ESMO) in Madrid the researchers presented the study describing Xalkori as a wonder drug. The drug Xalkori manufactured by Pfizer Incorporation is new in the market and is made to treat a rare type of lung cancer- the non small cell lung cancer (NSCLC). A clinical trial has shown surprising effects of Xalkori in reducing the size of this tumour and can be an effective treatment for people suffering from this uncommon form of illness related to gene defect.

The lead investigator Dr. Alice Shaw, from Boston’s Massachusetts General Hospital Cancer Center, reported that this clinical trial is the first solid study to establish crizotinib’s activity in victims of lung cancer who are tested positive for ROS1 and confirms that ROS1 is an authentic therapeutic target in those patients.

The database of the study involved 50 individuals diagnosed with NSCLC with a mutation in ROS1 gene. Out of 50, 36 patients consuming the drug showed shrinkage in the tumor size. This made a remarkable conclusion of 72 percent people benefiting from Pfizer medication through reduction in their fatal tumors. Moreover intake of Xalkori on a regular basis can actually halt the progression of the disease. This halt in the tumor growth was noted in nine patients.

Dr. Shaw in a separate statement stated that resistance with Xalkori develops much later as compared to other therapies used for treating lung cancers or melanoma.

Xalkori, with chemical name crizotinib, is approved from the US Centre for Disease Control and Prevention (CDC) for treating people with NSCLC having ALK fusion gene resulting from a mutation. This defective alteration in the genetic constituent of ALK plays a critical role in the growth of NSCLC; the same thing is witnessed in ROS 1 gene mutation too. However the clinical trial focused on the lung cancer due to rearrangements in ROS 1 gene only.

The medicine also serves spot diagnosis for detecting mutation in the ALK protein that occurs in 4 percent of individuals suffering from the disease. One important thing that should be kept in mind is that this Pfizer medication has longer duration of action, if taken twice daily, the medicine shows response within 17 month approximately.

Categories